2026-03-30 07:09:03
Sunvozertinib, a next-gen EGFR-TKI, offers breakthrough efficacy for EGFR-mutated NSCLC patients. Designed to overcome resistance and tackle brain metastases, it provides a promising new option. Explore dosing guidelines, AE management, monitoring strategies, and long-term treatment insights.